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Abstract
Malaria incidence in Myanmar has significantly reduced over recent years, however, com-
pleteness and timeliness of incidence data remain a challenge. The first ever nationwide
malaria infection and seroprevalence survey was conducted in Myanmar in 2015 to better
understand malaria epidemiology and highlight gaps in Annual Parasite Index (API) data.
The survey was a cross-sectional two-stage stratified cluster-randomised household survey
conducted from July-October 2015. Blood samples were collected from household mem-
bers for ultra-sensitive PCR and serology testing for P. falciparum and P. vivax. Data was
gathered on demography and a priori risk factors of participants. Data was analysed nation-
ally and within each of four domains defined by API data. Prevalence and seroprevalence of
malaria were 0.74% and 16.01% nationwide, respectively. Prevalent infection was primarily
asymptomatic P. vivax, while P. falciparum was predominant in serology. There was large
heterogeneity between villages and by domain. At the township level, API showed moderate
correlation with P. falciparum seroprevalence. Risk factors for infection included socioeco-
nomic status, domain, and household ownership of nets. Three K13 P. falciparum mutants
were found in highly prevalent villages. There results highlight high heterogeneity of both P.
falciparum and P. vivax transmission between villages, accentuated by a large hidden reser-
voir of asymptomatic P. vivax infection not captured by incidence data, and representing
challenges for malaria elimination. Village-level surveillance and stratification to guide inter-
ventions to suit local context and targeting of transmission foci with evidence of drug resis-
tance would aid elimination efforts.
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Introduction
The incidence of malaria in Myanmar has reduced significantly in recent years, falling by over
80% from a reported 1341.8 cases per 100,000 population in 2005 to 253.3 cases per 100,000
population in 2014 [1]. Similarly, malaria mortality fell by over 90% from 3.79 deaths per
100,000 to 0.25 per 100,000 over the same period. This trend reflects a corresponding increase
in political and financial commitment from the Myanmar government and partners. Efforts
resulted in strengthened malaria prevention and case management interventions, including
deployment of village health workers (VHWs) and large-scale long-lasting insecticide-treated
net (LLIN) distribution. Along with the rest of the Greater Mekong Sub-region (GMS) coun-
tries, the Myanmar national malaria control programme (NMCP) has drafted a strategy to
eliminate malaria by 2030 [2, 3]. Despite this, Myanmar has the highest incidence of any coun-
try in the GMS, evidence of artemisinin resistance, challenges of highly mobile population
groups, remote and hard-to-reach areas of high transmission and outdoor biting vectors pre-
senting obstacles to meeting this malaria elimination goal [4–7]. Completeness and timeliness
of collation of surveillance data remains a significant challenge in some regions, particularly
those that are remote and the true incidence of malaria in the country may, therefore, be
underestimated [8].
Prevalence surveys can highlight gaps in epidemiological understanding and if conducted
regularly can measure the rate of impact of interventions on decreasing transmission. There
has been increasing interest in the use of highly sensitive infection tests and serological meth-
ods in monitoring malaria transmission intensity in low transmission settings where preva-
lence is low since a large proportion of infections are asymptomatic and low density and thus
missed by conventional diagnostic methods [9, 10]. These methods can also provide detail on
within country heterogeneity of infection when analysed alongside spatial data and have the
potential to inform control and elimination programmes.
Here, we present results from this survey in relation to geography, incidence data and asso-
ciated risk factors to better understand the epidemiology of malaria in Myanmar and the chal-
lenges faced by drug resistance and ultimately malaria elimination.
Methods
The MIS protocol, questionnaire and tools were submitted to the Ethics Review Committee on
Medical Research Involving Human Subjects, Department of Medical Research. Following
defence of the submission full ethical approval was granted by the committee on 21/07/2015
(Letter Number: 59/ Ethics 2015, dated 21/07/2015)."
Study area
Myanmar (Burma) sits within the GMS, sharing borders with Thailand, China, India and Ban-
gladesh. In 2015, Myanmar had an estimated population of 53,900,000, and an estimated
malaria at-risk population of 32,120,000 residing in 15 malaria endemic states/regions [11].
Study design and sampling procedure
The Myanmar Malaria Indicator Survey (MIS) was a national cross-sectional household survey
conducted from July to October 2015. The survey used a two-stage stratified cluster-rando-
mised design, with a cluster defined as a ‘village’ and a ‘household’ as the sample unit. All
malaria endemic townships were included and were categorised into four non-contiguous
strata, termed domains, three based on intensity of malaria transmission using API data from
the township level (Domain 1—API >5; Domain 2—API 1–5; Domain 3—API <1) and non-
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state areas included in a separate fourth domain due to limited incidence data and variable
administrative structures (Fig 1).
Townships were randomly selected with probability proportionate to size (PPS) and with
replacement to ensure the required number of clusters within each domain was reached. One
village tract/ward (VT/W) per selected township was randomly selected with uniform proba-
bility. In each selected VT/W, field teams updated village level population and one village per
VT/W was randomly selected by PPS. In each selected village, field teams updated household
listings to include all registered and non-registered households at the time of the survey and
then randomly selected 31 households for participation. In areas covered by Domain 4 (non-
state areas), administrative systems were independent and unique. In each area, the survey
team interposed the government of Myanmar township boundaries and made random
Fig 1. Map of Myanmar showing location of the four sampling domains. Domain 1: API>5; Domain 2: API 1–5;
Domain 3: API<1; Domain 4: non-state areas.
https://doi.org/10.1371/journal.pone.0252957.g001
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selection of townships with PPS. Available population data supplied by non-state actors was
then used to make random selection with PPS of villages per township. Households were
selected in the same manner as in the other domains. Certain areas that were absolutely inac-
cessible at the time of surveying due to active conflict or flooding were excluded from the sam-
pling frame.
Sample size
Sample size was calculated based on assumed prevalence levels detectable by PCR in each of
the strata and using the standard formula for proportions, assuming a minimum precision of
0.01, a non-response rate of 10%, a design effect of 2.0, average household size of 4.5 and selec-
tion of 31 households per cluster. Based on this, a total 20,138 individuals from 4,495 house-
holds and 145 clusters across the four domains were required.
Data collection
Prior to data collection, fully informed consent was gathered from the head of the household
on behalf of all household members and for children, where applicable, for both questionnaire
information and blood collection. Study information was provided in written and/or verbal
form in a language understandable to the participant and written consent was provided by sig-
nature or thumb print.
In each selected household, a standard questionnaire was administered to the head of the
household or his/her representative. The questionnaire was designed to gather data on factors
related to demographic background, including age, sex and wealth of the household; malaria
risk factors, including fever, travel and forest-going habits; net ownership and usage, including
type of net; case management practices, including healthcare seeking behaviour; and knowl-
edge of malaria. These data were gathered on all household members, including temporary vis-
itors staying in the household at the time of the survey. A traveller was defined as a household
member who has travelled and stayed overnight away from home in the previous six months.
A forest-goer was defined as a household member who sometimes goes to the forest and stays
there overnight.
Upon obtaining informed consent, all household members aged over six months present in
the households were tested for malaria infection by rapid diagnostic test (RDT) (brand: SD
Bioline Pan P. falciparum/P. vivax) and asked to provide four dried blood spots on filter paper
for subsequent PCR, K13 molecular analysis and serological testing. Blood spots from each
individual from a finger prick using a sterile lancet and necessary measures to ensure sterile
blood collection (alcohol wipes, cotton wool, etc.). The survey team revisited households up to
three times to get blood samples from all household members. GPS coordinates were recorded
in every sampled household and from a central point in each cluster to assess for geographical
clustering of infection, except in domain 4 where no geolocation data were provided due to
local sensitivities.
Laboratory analyses
Two filter paper samples (one FTA Elute card containing two bloodspots for PCR and K13;
and one 3MM Whatman card containing one bloodspot for serology) and one extra blood
spot were prepared for each participant. Samples were labelled using the CDC bar coding sys-
tem. All blood samples were collected using individual capillary tubes, spotting the samples on
Whatman 3MM filter paper as described [12]. DBS samples were air-dried, placed in a sealed
plastic pouch with desiccant and stored at room temperature until analysed in the laboratory
(up to 6 months).The DBS were used for: 1) detection of malaria species and, 2) seroprevalence
PLOS ONE High heterogeneity in the prevalence and seroprevalence of Plasmodium infection in Myanmar
PLOS ONE | https://doi.org/10.1371/journal.pone.0252957 June 9, 2021 4 / 20
analysis. Nucleic acids were extracted from dried blood spots using an optimized protocol as
described by Zainabadi et al. [12]. The prevalences of the two major Plasmodium species (P.
falciparum and P. vivax) were estimated using ultrasensitive PCR with a detection limit of 20
parasites per millilitre, as previously described by Adams et al. [13] P. falciparum positive sam-
ples were subsequently tested for mutations in the Kelch gene on chromosome 13 (K13), a
molecular marker for artemisinin resistance, as described in Ouattara et al. [14].
For serological analysis, dry blood spots were eluted and tested for IgG antibodies to P. fal-
ciparum and P. vivax AMA1 and MSP1-19 as previously described [15]. Briefly, sera were
eluted from 3mm dried blood spots and prepared as a 1/200 dilution in 1XPBS/0.05% tween.
Each antigen was coated to microtitre plates (Immulon4) and incubated overnight at 4˚C. Fol-
lowing a wash step (3 times in PBS-T) the plates were blocked for 3 hours with 1xPBS/0.05%
Tween/1% milk powder. Following a further wash step samples were added in duplicate at a
dilution of 1/1000 (MSP) and 1/2000 (AMA). Species specific positive sera were used on each
plat and to enable the adjustment of results to account for plate to plate variation; for P.falcipa-
rum, CP3 a hyper immune positive pool from Tanzania and for P.vivax, 72/096 a standard
with high reactivity to P.vivax obtained from NIBSC. Plates were then incubated overnight at
4˚C. The following day the plates were washed 5 times and incubated for 3 hours with an anti-
human IgG-HRP (DAKO) diluted to 1/5000, for 3 hours. The plates were washed a further 5
times and incubated for 20 minutes with Sigmafast OPD for 20 minutes in the dark, the plates
were then read at 492 nm. A titration curve was fitted to the ODs obtained for the standard
plasma dilutions by least squares minimisation using a three variable sigmoid model and the
solver add-in in Excel (Microsoft), assuming an arbitrary value of 1000 Units/ml of antibody
against each antigen in the standard pool. OD values were converted to units/ml using this fit-
ted curve [15]. Cut-offs to define antigen specific seropositivity were generated using the mix-
ture model and analysed using standard measures [16, 17]. A sample was considered positive if
OD values were above the seropositivity threshold for at least one of the two antigens.
Data analysis
Data from paper-based questionnaires were double entered into EpiData and analysed using
Stata 14.1 with figures produced in R 3.4.2 [18, 19]. Analysis was adjusted using the appropri-
ate weights for households and individuals, respectively according to the study design.
Descriptive statistics were gathered on demographics of the sample population and of malaria
infection and exposure, disaggregated by species, calculated nationally and per domain. Socio-
economic status of HHs were assessed by splitting HHs into wealth quintiles, with quintile 1
(Q1) as the poorest 20% of HHs, and quintile 5 (Q5) as the wealthiest 20% of HHs. All propor-
tions were calculated with 95% confidence intervals (CI) to indicate significant differences in
estimates both between and within domains.
Since RDT positivity rates were low, primary outcomes were PCR prevalence and seroprev-
alence of P. falciparum and P. vivax. Using available GPS coordinates, clusters were mapped
according to prevalence and seroprevalence of P. falciparum and P. vivax to explore potential
geographic clustering of infection. To maintain anonymity in Domain 4, clusters were mapped
to the GPS coordinates of the central township to which they belonged as available from Goo-
gle Maps and Wikipedia [20, 21].
To compare routine malaria incidence with survey prevalence data, cluster prevalence data
was aggregated at the township level and prevalence/seroprevalence was plotted against town-
ship API (defined as the number of malaria cases per 1000) data collected during 3-month
design phase of the survey (e.g. Domain classification of townships). For each plot a Loess
curve was generated to characterise the relationship between prevalence and API.
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Risk factor analysis was conducted using logistic regression modelling with PCR positive/
seropositive P. falciparum or P. vivax infection as the dependent variable. Crude odds ratios
(ORs) and 95% CI for each species of infection were generated from independent variables
related to demographic factors, net coverage and usage, history of fever, healthcare-seeking
behaviours, risk group categories and knowledge indicators of the head of the household. Vari-
ables with a p-value�0.05 were included in a multivariable model and step-wise backwards
deletion of variables was done until a final multivariable model was generated with only signif-
icant associations included. Age and sex were controlled for in all final models.
Results
A total of 4,371 households comprising 20,638 household members were included in the sur-
vey (Table 1). Blood samples were collected from 13,873 (67%) household members for PCR
analysis of which 13,726 could be matched to cluster data and 13,716 to individual level data.
The 157 (1.13%) samples unable to be matched were due to a loss of questionnaire data from
one cluster and incorrect identifiers on some blood samples. The four DBS were prioritised for
PCR and K13 testing, so if a DBS did not have enough material for testing, the next spot would
be used for PCR/K13, while remaining DBS were used for serological analysis. This resulted in
11,653 blood samples available for serological analysis.
Among all household members, there was no difference in the proportion that gave blood sam-
ples by domain, wealth quintile or urban/rural area, though there was variation in the level of par-
ticipation of individual clusters (ranging from 18.9% to 93.0% per cluster) and several clusters
achieved less than 50% of household members contributing blood samples to the analysis, particu-
larly in Domain 4 (S1 Table). Significantly fewer males, children aged less than five years and trav-
ellers contributed blood samples for PCR analysis. For serology, significantly fewer travellers,
individuals with any schooling, and children aged less than 5 years provided blood samples for
analysis. Pregnant women were the most covered group for both diagnostic procedures (S1 Table).
Prevalence and seroprevalence
Of 13,648 RDTs conducted, only 10 positive cases were identified including eight P. falciparum
and two P. vivax infections. Since the number of cases was so low, this was not included as a
primary outcome in subsequent analyses. Overall, PCR prevalence of Plasmodium infection
was 0.74%, 95% CI [0.49–1.13], but was significantly higher in Domain 4 at 10.96%, 95% CI
[5.63–20.25], followed consecutively by Domain 1, Domain 2 and finally Domain 3 (Fig 2).
P. vivax made up 70% of infections. Prevalence of P. vivax was 0.52%, 95% CI [0.35–0.77] over-
all, but significantly higher in Domain 4 (10.39%, 95% CI [5.38–19.10]) followed by Domain 1
(2.26%, 95% CI [1.52–3.35]). Prevalence of P. falciparum was low at only 0.17%, 95% CI [0.07–
0.41] and did not differ significantly by domain. No P. falciparum cases were detected in
Domain 3. There were 28 mixed infections identified, giving an overall prevalence of 0.05%,
95% CI 0.01–0.21, but the majority (n = 20) were detected in Domain 1.
Table 1. Sample size achieved across domains.
Domain 1 Domain 2 Domain 3 Domain 4 Total
No. of households 1,734 986 757 894 4,371
No. of people in households 8,545 4,544 3,251 4,298 20,638
No. (%) of household members with PCR sample� 5,687 (66.6) 3,121 (68.7) 2,254 (69.3) 2,664 (62.0) 13,726 (66.5)
No. (%) of household members with serology sample 4,685 (54.8) 2,724 (60.0) 2020 (62.1) 2,224 (51.8) 11,653 (56.5)
�10 samples could be matched to cluster but not to individual questionnaire data, so for individual analysis n = 13,716
https://doi.org/10.1371/journal.pone.0252957.t001
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Seroprevalence was 16.01%, 95% CI [12.89–19.72] overall and was highest in Domains 4
and 1 (36.45%, 95% CI [30.92–42.36] and 34.26%, 95% CI [28.77–40.19], respectively) and sig-
nificantly lowest in Domain 3 (10.84%, 95% CI [7.41–15.60], Fig 2). P. falciparum seropreva-
lence was over two-times higher than P. vivax. P. falciparum seroprevalence was significantly
lower in Domain 3 and appeared highest in Domains 1 and 4 though CIs overlapped with
Domain 2. P. vivax seroprevalence was highest in Domain 4, followed consecutively by
Domain 1, 2 and finally 3 (though CIs overlap between each level). Antibody responses split by
age showed there were individuals with marked antibody responses in all age groups, including
children aged 1–10 (Fig 3).
K13
Of the total 80 P. falciparum infections identified, 17 had high enough parasite load to qualify
for K13 testing. Of these, three (17.7%) had a mutation in the F446I gene, each from three dif-
ferent clusters in Domain 1, two of which were in Pinlebu township, north-western Myanmar.
Fig 2. usPCR prevalence (top) and seroprevalence (bottom) of P. falciparum, P. vivax and mixed infection in
Myanmar nationwide and within each of four domains. Mixed infection not included in separate P. falciparum/P.
vivax prevalence figures.
https://doi.org/10.1371/journal.pone.0252957.g002
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Mapping of clusters
Clusters (villages) were plotted based on prevalence and seroprevalence of both P. falciparum
and P. vivax (Fig 4). Clusters of higher P. falciparum prevalence were observed in Sagaing
Region, north-west Myanmar (�latitude 24o longitude 95.5o). Two of these clusters were from
the same township, Pinlebu, with prevalences of 18.33% and 9.49%, one of which also con-
tained a K13 mutant. These were followed by lower prevalences in another township of Saga-
ing (4.05%) and two clusters in Ann township of Rakhine State, south-west Myanmar (2.33%
and 2.20%,�latitude 19o longitude 94o). The highest prevalence clusters for P. vivax were in
Domain 4, including 60.34% from a cluster in Yephyu township, Thanintharyi State; 42.40%
and 29.91% from two clusters in Yay township, Mon State; and 19.79% from a cluster in Mya-
waddy township, Kayin State (all in the south-east tip of Myanmar).
Seroprevalence was higher and more widespread throughout the country particularly for
P. falciparum. Although there were many clusters without any evidence of infections by PCR
(coloured in black), there were only few clusters without any seropositive individuals.
Fig 3. Normalised age-stratified antibody responses to P. falciparum antigens A] PfAMA, B] PfMSP-1, and P. vivax antigens C] PvAMA, D] PvMSP-1.
Horizontal red lines represent antigen-specific cut-off valus.
https://doi.org/10.1371/journal.pone.0252957.g003
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Asymptomatic infection and risk factors for infection
The vast majority of PCR-positive P. vivax infections were asymptomatic, defined as not hav-
ing current fever nor reported fever in the previous two weeks (99.53%, 95% CI [94.84–99.81])
and in Domains 2 and 3, all P. vivax infections were asymptomatic. P. falciparum had a higher
proportion of symptomatic infection compared to P. vivax (22.99%, 95% CI [6.49–56.22] ver-
sus 0.47%, 95% CI [0.19–1.12], Pearson’s chi-square = 82.3, p<0.001).
Risk factors for PCR positivity and seropositivity among the whole population sample dif-
fered slightly between Plasmodium species and per domain (Fig 5). PCR prevalence of P. falcip-
arum was associated with older age groups, wealth quintile, staying in the forest and with
current fever. It was also associated with HH ownership of bed nets and with knowledge of
malaria. P. vivax prevalence was associated with age, domain, absence of fever and owning suf-
ficient nets, and was lower in pregnant women.
As expected, seropositivity increased with age, and whilst there were still seropositive chil-
dren aged less than 5 years for both P. falciparum (prevalence in under-fives ranging from 1.2
to 3.1% across the 4 domains) and P. vivax (ranging from 2.2 to 3.7% across domains) the
majority of these had antibody levels close to the seropositivity threshold. Seroprevalence of
P. falciparum was also associated with wealth quintile, staying in the forest and ownership of
nets, as well as domain, and being PCR positive (Fig 5). P. vivax seroprevalence was also
Fig 4. Maps showing prevalence (left column) and seroprevalence (right column) of P. falciparum (top row) and
P. vivax (bottom row) in each sampled cluster. Each dot represents one cluster (one village) coloured according to
level of prevalence or seroprevalence. Black dots indicate clusters where no positive PCR or serology cases were
identified.
https://doi.org/10.1371/journal.pone.0252957.g004
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associated with age and domain, as well as being PCR positive, having current fever, ownership
of nets and knowledge of nets (Fig 5).
Analysis of the whole population sample, however, hides interesting differences in risk fac-
tors between domains for both prevalence and seroprevalence of each species (Tables 2–5).
For example, P. falciparum infection was associated with current pregnancy in Domain 1, with
current fever and staying in the forest in Domain 2, and with being a traveller in Domain 4
(Table 2). P. vivax infection was associated with being a forest-goer in Domain 1 and 4, but
not in Domain 2 (Table 3). In Domain 4, being from a rural area or lower wealth quintile was
also associated with P. vivax infection but these were not significant in the other domains. For
P. falciparum seropositivity, wealth quintile was a significant factor across all domains, but the
importance of sex and age differed with males having higher odds of being seropositive in
domains 1 and 4, but not domains 2 or 3, and age being significant in domains 1, 2, and 3 but
not domain 4 (Table 3). P. falciparum seropositivity was also associated with living in a rural
area in domain 4, being a forest-goer in domain 3, and having current fever in domain 1. Simi-
larly for P. vivax seropositivity, the importance of sex differed between domains, as well as
wealth quintile (domain 1), current fever (domain 3) and living in a rural area (domain 4).
Interestingly, higher odds of infection and exposure indices were associated with higher
ITN/LLIN ownership and/or knowledge of ITN as a prevention tool for both plasmodia spe-
cies and in most domains.
Fig 5. Forest plots showing Adjusted Odds Ratios (AOR) for risk factors related to being positive by usPCR or by serology across the whole study sample
(n = 13,716 for PCR and 11,653 for serology). A] Prevalence of P. falciparum, B] PCR prevalence of P. vivax, C] Seroprevalence of P. falciparum, D] Seroprevalence of P.
vivax. Factors shown are those that remained significant in multivariate logistic regression analyses (plus sex and age group).
https://doi.org/10.1371/journal.pone.0252957.g005
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Association between incidence and prevalence
Township API data acquired during sampling was plotted against prevalence and seropreva-
lence figures aggregated by township (Fig 6). No clear trends were observed for either P. vivax
and P. falciparum PCR prevalence and township API. A positive relationship was observed
between increasing API and increasing seroprevalence to P. falciparum. However, the associa-
tion between API and P. vivax was less clear with a positive association observed only until
seroprevalence estimates of 25%.
Discussion
The results of the first ever MIS in Myanmar reveal programmatically important epidemiologi-
cal findings not apparent in routine surveillance data. Use of RDTs, now a common tool for
identifying malaria infection in the field, only detected a tiny fraction of infections identified
by PCR. RDTs can be useful for diagnosis of clinical disease but, as demonstrated here, are not
a good surveillance tool, particularly in a context where asymptomatic and sub-patent infec-
tion may be highly prevalent [22]. Use of PCR, however, was able to detect a low-level national
prevalence of just 0.74% for all-species Plasmodium infection, or 0.17% and 0.52% for species-
specific P. falciparum and P. vivax infection, respectively. However, these overall estimates
mask huge variation between the domains which ranged from an all-species prevalence of
10.96% in Domain 4 to 0.19% in Domain 3. Species-specific prevalence figures show that P.
falciparum infections were relatively low and uniform across the country whereas P. vivax,
Table 2. Domain specific adjusted ORs for P. falciparum infection1.
Crude OR Adjusted OR
Prevalence, % (95% CI) OR 95% CI p-value OR 95% CI p-value
D1 Sex Female 0.80 (0.27–2.37) 1 1
Male 1.04 (0.44–2.46) 1.31 0.82–2.11 0.3 1.44 0.88–2.36 0.1
Age group <5 0.27 (0.04–2.00) 1 1
5 to 14 0.75 (17–3.28) 2.80 0.42–18.60 0.3 2.95 0.45–19.48 0.3
15+ 1.00 (0.40–2.46) 3.7 1.03–13.31 0.05 3.59 1.00–12.87 0.05
Current pregnancy 2.31 (0.60–8.41) 2.66 1.40–5.06 0.004 3.09 1.61–5.95 0.001
HH owns at least one ITN 1.31 (0.41–4.05) 5.18 1.23–21.80 0.03 4.75 1.13–20.01 0.03
HH head went to school 0.58 (0.25–1.32) 0.33 0.18–0.61 0.001 0.36 0.19–0.66 0.001
D2 Sex Female 0.33 (0.12–0.87) 1 1
Male 0.48 (0.12–1.88) 1.49 0.60–3.65 0.4 1.06 0.52–2.15 0.9
Age (per year) n/a 1.13 1.04–1.23 0.005 1.07 0.94–1.21 0.3
Current fever 5.71 (1.91–15.86) 20.85 2.98–145.70 0.003 35.42 6.03–207.86 < .001
Forest-goer 5.81 (1.08–25.95) 33.05 5.02–217.48 0.001 42.15 4.37–406.20 0.002
Head of HH went to school 0.10 (0.02–0.40) 0.07 0.03–0.19 < .001 0.08 0.03–0.22 < .001
D4 Sex Female 0.17 (0.06–0.51) 1 1
Male 0.64 (0.27–1.52) 3.72 1.00–13.88 0.05 3.13 0.92–10.59 0.07
Age group <5 0.30 (0.04–2.52) 1 1
5 to 14 0.40 (0.12–1.31) 1.32 0.11–15.41 0.8 1.34 0.12–15.17 0.8
15+ 0.39 (0.17–0.86) 1.27 0.12–12.93 0.8 1.00 0.09–10.55 1
Traveller 3.00 (0.77–11.00) 10.47 2.39–45.88 0.003 8.21 1.90–35.36 0.006
HH head knows ITN is
prevention method
1.57 (0.35–6.73) 5.01 1.03–24.37 0.05 4.38 1.07–17.92 0.04
1Models for domain 3 were not able to be completed due to lack of sufficient infections
https://doi.org/10.1371/journal.pone.0252957.t002
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made up the vast majority of infection in all domains and accounted for the observed heteroge-
neity. Given that serology captures both current and past infection, seroprevalence was expect-
edly higher at 16.01%, but showed similar variation between domains. In contrast to PCR data,
the dominant Plasmodium species detected by serology was P. falciparum, including in young
children. In comparing API data with prevalence and seroprevalence, where API was <25 per
1000 population, serology was able to capture a wider range of API variability than PCR, par-
ticularly for P. falciparum which showed a strong positive correlation between API with sero-
prevalence, although there was significant variation. Although there was an initial upward
trend in API with P. vivax seroprevalence, this correlation was no longer apparent at preva-
lences greater than 25%.
The dominance of P. vivax prevalence is in contrast to routine surveillance data, which
detects incident symptomatic clinical cases only and places P. falciparum as the major malaria
species (75%) in Myanmar [11]. This is to be expected since P. falciparum is associated with
higher parasite densities and more serious clinical outcomes than P. vivax, and as such leads to
the poor correlation of P. vivax prevalence with API data we have shown [23, 24]. Whether
this reservoir is important for transmission is under debate. While some studies have shown
Table 3. Domain specific adjusted ORs for P. vivax infection1.
Prevalence % (95%CI) Crude OR Adjusted OR
OR 95% CI p-value OR 95% CI p-value
D1 Sex Female 1.25 (0.78–2.00) 1 1
Male 3.65 (2.44–5.43) 2.98 2.19–4.06 < .001 3.04 2.18–4.24 < .001
Age group <5 0.81 (0.18–3.55) 1 1
5 to 14 1.54 (0.68–3.43) 1.90 0.33–11.10 0.5 2.02 0.35–11.61 0.4
15+ 2.59 (1.79–3.75) 3.24 0.70–15.03 0.1 3.41 0.76–15.34 0.1
Forest-goer 7.83 (3.50–16.57) 4.01 1.78–9.01 0.001 2.42 1.07–5.46 0.04
HH owns sufficient LLINs 5.02 (2.98–8.34) 3.95 2.14–7.31 < .001 3.90 2.12–7.16 < .001
HH head knows sleeping under net
is prevention method
1.68 (1.06–2.63) 0.58 0.38–0.87 0.01 0.58 0.39–0.88 0.01
D2 Sex Female 0.53 (0.24–1.19) 1 1
Male 0.99 (0.49–1.99) 1.87 1.09–3.22 0.02 1.96 1.13–3.40 0.02
Age (per year) n/a 1.01 0.98–1.03 0.6 1.09 0.98–1.20 0.1
HH owns sufficient LLINs 1.65 (0.66–4.06) 2.86 1.11–7.35 0.03 2.97 1.13–7.83 0.03
D4 Sex Female 10.56 (4.50–22.82) 1 1
Male 10.06 (6.09–16.17) 0.95 0.57–1.57 0.8 0.89 0.51–1.56 0.7
Age group <5 4.94 (1.27–17.30) 1 1
5 to 14 12.48 (4.73–29.07) 2.74 1.58–4.76 0.001 1.75 0.81–3.77 0.1
15+ 10.09 (5.86–16.82) 2.16 0.83–5.60 0.1 1.28 0.41–3.93 0.7
Area Rural 12.13 (6.03–22.90) 10.87 2.46–48.05 0.003 9.23 1.99–42.78 0.006
Quintile Q1 (poorest) 12.28 (5.69–24.51) 1 1
Q2 12.04 (6.72–20.62) 0.98 0.63–1.52 0.9 0.85 0.55–1.33 0.5
Q3 8.06 (3.66–16.81) 0.63 0.35–1.12 0.1 0.62 0.36–1.06 0.08
Q4 8.44 (3.63–18.42) 0.66 0.35–1.25 0.2 0.70 0.37–1.34 0.3
Q5 0.93 (0.10–7.94) 0.07 0.01–0.58 0.02 0.06 0.01–0.51 0.01
Forest-goer 18.06 (10.13–30.12) 2.02 1.22–3.35 0.008 2.10 1.37–3.20 0.001
Attended school 12.64 (6.25–23.91) 2.00 1.31–3.05 0.002 1.90 1.20–3.01 0.008
HH owns sufficient ITNs 13.59 (7.33–23.83) 2.12 1.19–3.79 0.01 1.69 1.02–2.80 0.04
1Models for domain 3 were not able to be completed due to lack of sufficient infections
https://doi.org/10.1371/journal.pone.0252957.t003
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Table 4. Crude and adjusted odds ratios for P. falciparum seropositivity per domain.
Crude OR Adjusted OR
Prevalence % (95% CI) OR 95% CI p-value OR 95% CI p-value
D1 Sex Female 27.57 (22.12–33.77) 1 1
Male 33.43 (28.26–39.03) 1.32 1.15–1.51 < .001 1.47 1.25–1.72 < .001
Age group <5 3.01 (0.73–11.57) 1 1
5 to 14 10.48 (6.83–15.75) 3.77 0.80–17.79 0.09 5.06 1.25–20.47 0.02
15+ 36.61 (29.68–44.15) 18.6 4.44–77.93 < .001 29.66 8.04–109.41 < .001
Wealth quintile Q1 31.92 (26.28–38.13) 1 1
Q2 35.47 (27.73–44.04) 1.17 0.88–1.57 0.3 1.05 0.73–1.53 0.8
Q3 30.59 (22.46–40.12) 0.94 0.68–1.29 0.7 0.79 0.53–1.16 0.2
Q4 27.94 (21.01–36.12) 0.83 0.57–1.21 0.3 0.66 0.42–1.05 0.08
Q5 23.73 (19.51–28.55) 0.66 0.48–0.92 0.02 0.57 0.37–0.88 0.01
PCR positive 71.54 (58.95–81.49) 6.23 3.73–10.41 < .001 4.76 2.61–8.69 < .001
Current Fever 46.13 (33.37–59.42) 2.02 1.21–3.36 0.008 2.43 1.49–3.98 0.001
HH owns sufficient ITNs/LLINs 39.39 (30.44–49.10) 1.78 1.23–2.57 0.003 1.72 1.14–2.61 0.01
D2 Sex Female 19.21 (13.23–27.06) 1 1
Male 20.50 (14.58–28.05) 1.08 0.90–1.30 0.4 1.17 0.96–1.42 0.1
Age group <5 3.08 (1.00–9.10) 1 1
5 to 14 5.48 (2.97–9.88) 1.83 0.71–4.73 0.2 3.6 0.74–17.47 0.1
15+ 23.90 (16.39–33.48) 9.89 3.05–32.11 < .001 24.34 3.85–153.92 0.001
Wealth quintile Q1 26.67 (17.47–38.46) 1 1
Q2 25.22 (14.84–39.48) 0.93 0.66–1.30 0.7 0.86 0.62–1.19 0.3
Q3 24.23 (16.32–34.40) 0.88 0.62–1.25 0.5 0.9 0.61–1.32 0.6
Q4 19.40 (13.56–26.99) 0.66 0.41–1.06 0.08 0.61 0.38–0.98 0.04
Q5 12.55 (9.35–16.65) 0.39 0.23–0.67 0.001 0.41 0.24–0.69 0.002
PCR positive 78.65 (60.30–89.94) 15.79 6.99–35.65 < .001 11.79 4.72–29.44 < .001
HH Head knows malaria can be
prevented
17.58 (12.65–23.89) 0.65 0.47–0.91 0.01 0.69 0.50–0.96 0.02
HH owns sufficient ITNs/LLINs 32.35 (19.40–48.72) 2.28 1.21–4.31 0.01 2.28 1.16–4.48 0.02
D3 Sex Female 9.15 (5.39–15.11) 1 1
Male 7.10 (4.60–10.81) 0.76 0.48–1.20 0.2 0.72 0.44–1.20 0.2
Age group <5 1.88 (0.25–12.83) 1 1
5 to 14 3.74 (1.87–7.34) 2.03 0.39–10.54 0.4 2.24 0.38–13.22 0.4
15+ 9.55 (6.02–14.81) 5.52 0.72–42.16 0.1 6.15 0.69–54.93 0.1
Quintile Q1 10.09 (5.08–19.05) 1 1
Q2 8.17 (4.65–13.96) 0.79 0.40–1.58 0.5 0.78 0.39–1.54 0.5
Q3 10.90 (7.24–16.10) 1.09 0.58–2.05 0.8 0.98 0.51–1.88 1
Q4 7.28 (4.18–12.37) 0.7 0.36–1.37 0.3 0.61 0.30–1.25 0.2
Q5 3.68 (1.39–9.36) 0.34 0.13–0.87 0.03 0.27 0.12–0.63 0.004
Forest goer 21.47 (11.67–36.14) 3.17 1.67–5.99 0.001 2.49 1.39–4.48 0.004
HH owns sufficient ITNs/LLINs 20.92 (12.09–33.73) 3.25 1.63–6.49 0.002 3.5 1.94–6.33 < .001
HH Head heard BCC in previous 6
months
13.33 (7.27–23.18) 1.83 1.00–3.36 0.05 1.91 1.14–3.22 0.02
D4 Sex Female 28.48 (23.48–34.09) 1 1
Male 32.63 (26.39–39.56) 1.22 0.99–1.50 0.07 1.53 1.24–1.90 < .001
Age group <5 1.20 (0.26–5.26) 1 1
5 to 14 6.70 (5.17–8.65) 5.93 1.23–28.65 0.03 4.5 0.86–23.47 0.07
15+ 41.34 (33.86–49.24) 58.17 11.35–298.10 < .001 45.76 8.28–252.77 < .001
Area Rural 31.06 (25.37–37.38) 2.04 1.48–2.80 < .001 1.91 1.18–3.09 0.01
Quintile Q1 29.90 (22.79–38.13) 1 1
Q2 30.62 (23.97–38.18) 1.03 0.64–1.67 0.9 0.9 0.54–1.53 0.7
Q3 34.03 (23.43–46.52) 1.21 0.67–2.18 0.5 1.02 0.55–1.86 1
Q4 27.98 (20.82–36.47) 0.91 0.53–1.55 0.7 0.54 0.30–0.99 0.05
Q5 18.36 (11.83–27.38) 0.53 0.28–1.01 0.05 0.44 0.21–0.94 0.03
Slept under LLIN previous night 34.21 (28.34–40.61) 1.43 1.06–1.92 0.02 1.63 1.17–2.27 0.005
https://doi.org/10.1371/journal.pone.0252957.t004
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that asymptomatic and submicroscopic infections contribute to transmission, others have
shown very limited infectivity to mosquitoes, particularly in the Asian transmission context
[25–27]. A recent study, however, has suggested mosquito infection rates show positive corre-
lation with blood parasitaemia when P. vivax parasitaemia is >10 parasites/ul, and that this
may be the optimal diagnostic threshold since mosquito infection is rare at levels below this
threshold [28]. Moreover, P.vivax infections tend to reach peak gametocytaemia prior to
symptoms and are infectious before treatment this coupled with the relapse of infection due to
their dormant liver stage hypnozoites, means transmissibility is difficult to predict [29].
Table 5. Crude and adjusted odds ratios for P. vivax seropositivity per domain.
Crude OR Adjusted OR
Prevalence % (95% CI) OR 95% CI p-value OR 95% CI p-value
D1 Sex Female 14.03 (10.32–18.78) 1 1
Male 14.88 (11.77–18.65) 1.07 0.91–1.26 0.4 1.13 0.95–1.34 0.2
Age group <5 3.07 (1.06–8.56) 1 1
5 to 14 4.33 (2.00–9.12) 1.43 0.37–5.53 0.6 2.13 0.61–7.45 0.2
15+ 17.67 (13.18–23.26) 6.76 2.20–20.81 0.001 9.89 3.27–29.94 < .001
Wealth quintile Q1 17.17 (11.81–2429) 1 1
Q2 15.30 (10.77–21.28) 0.87 0.61–1.25 0.4 0.88 0.60–1.31 0.5
Q3 15.81 (11.24–21.76) 0.91 0.56–1.46 0.7 0.9 0.51–1.59 0.7
Q4 12.23 (8.42–17.43) 0.67 0.39–1.16 0.1 0.64 0.34–1.22 0.2
Q5 9.96 (7.08–13.84) 0.53 0.31–0.92 0.02 0.51 0.27–0.97 0.04
PCR positive 37.23 (27.25–48.44) 3.73 2.18–6.39 < .001 3.11 1.86–5.20 < .001
Attended school 12.96 (9.77–17.00) 0.61 0.40–0.93 0.02 0.60 0.38–0.94 0.03
D2 Sex Female 7.68 (5.56–10.52) 1 1
Male 9.85 (6.58–14.50) 1.31 1.00–1.72 0.05 1.44 1.09–1.92 0.01
Age group <5 3.65 (1.36–9.41) 1 1
5 to 14 4.33 (2.35–7.84) 1.19 0.53–2.67 0.7 2.09 0.94–4.64 0.07
15+ 9.88 (6.89–13.96) 2.89 0.99–8.45 0.05 5.22 1.59–17.15 0.008
PCR positive 48.67 (37.06–60.43) 10.95 5.90–20.31 < .001 9.43 4.37–20.33 < .001
Attended school 7.59 (5.29–10.78) 0.53 0.36–0.80 0.003 0.59 0.38–0.92 0.02
Slept under LLIN previous night 13.08 (9.56–17.64) 1.88 1.23–2.88 0.005 1.94 1.24–3.06 0.005
HH head knows sleeping under
net is prevention method
6.59 (4.70–9.15) 0.58 0.45–0.76 < .001 0.64 0.47–0.86 0.004
D3 Sex Female 2.72 (1.22–5.95) 1 1
Male 3.79 (1.57–8.85) 1.41 0.99–2.02 0.06 1.45 1.02–2.05 0.04
Age (per year) n/a 1.02 1.01–1.03 0.004 1.02 1.01–1.03 0.002
Current fever 11.24 (2.62–37.36) 4.06 1.36–12.17 0.01 4.11 1.50–11.26 0.008
HH Head attended school 2.88 (1.21–6.71) 0.55 0.35–0.87 0.01 0.62 0.40–0.96 0.03
D4 Sex Female 18.15 (14.17–22.94) 1 1
Male 20.55 (15.62–26.55) 1.17 1.01–1.35 0.04 1.14 0.97–1.36 0.1
Age group <5 2.24 (0.47–9.96) 1 1
5 to 14 7.15 (3.92–12.69) 3.36 0.74–15.26 0.1 2.19 0.60–9.18 0.3
15+ 25.06 (18.79–32.58) 14.56 2.74–77.41 0.003 9.82 1.79–54.00 0.01
Area Rural 20.04 (15.64–25.30) 3.28 1.89–5.70 < .001 2.51 1.56–4.05 0.001
PCR positive 44.22 (34.09–54.85) 3.89 2.49–6.09 < .001 3.65 2.30–5.78 < .001
HH owns at least one ITN 21.53 (16.69–27.32) 1.97 1.29–3.01 0.003 1.72 1.04–2.83 0.04
HH head knows sleeping under
net is a prevention method
24.68 (17.91–32.98) 1.57 1.16–2.11 0.004 1.42 1.15–1.74 0.002
https://doi.org/10.1371/journal.pone.0252957.t005
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Programmatically this is important because to achieve malaria elimination these relapses of
infection will need to be targeted to remove the P. vivax infection reservoir. In practice this
will be a challenge given that sub-clinical infections are poorly detected by RDTs and the only
currently available radical cure for P. vivax, Primaquine, can be fatal in individuals with G6PD
deficiency [30, 31]. P. vivax also doesn’t respond as well to the mainstays of vector control—
ITNs/LLINs and IRS—largely due to its hypnozoite stage and association with outdoor and
early biting vectors [32, 33]. Personal protection tools against outdoor biting mosquitoes are
required that are effective and affordable for the target populations.
The higher seropositivity from P. falciparum may be due to the timing of data collection,
much of which was after the transmission season, or because the ELISA assay used was origi-
nally developed to detect responses to P. falciparum antigens and thus may be more sensitive
in detecting those. P. falciparum also circulates at higher parasite densities that induce higher
antibody levels than P. vivax [34] and this is likely to induce more detectable antibody levels.
Further analyses could be conducted to run the assay at higher serum concentrations against
more antigenic targets to optimize P. vivax antibody detection [35].
The difference exhibited in prevalence between domains (API strata) supports the stratifica-
tion design of the survey and is important to consider in the design of future surveys to capture
Fig 6. Association of prevalence and seroprevalence with incidence data, aggregated by township and split by P.
falciparum (top) and P. vivax (bottom).
https://doi.org/10.1371/journal.pone.0252957.g006
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important heterogeneities between regions. It also highlights the need for the Myanmar
NMCP to be able to stratify its surveillance and approaches to interventions to suit the differ-
ent transmission intensities in the country, including in the types of risk factors used to target
high-risk population groups [36]. Moreover, the variation in prevalence was high even
between individual clusters, supporting the need for village level stratification of malaria risk
and village level case surveillance, particularly to identify hotspots and areas of drug resistance
for a rapid intervention response. Domain 3, represents a zone approaching elimination in
which new strategies for elimination could be implemented for the rest of the country to fol-
low. Interestingly, across all domains, higher odds of malaria infection were associated with
greater household net ownership and/or use, as well as knowledge of malaria and prevention
methods. This seems counterintuitive and is likely because net distribution and behaviour
change activities are targeted to areas of Myanmar with higher malaria caseloads and
transmission.
Despite their differences, the use of serology in combination with PCR was firstly able to
enrich findings by mapping areas (village data aggregated geographically) of potential high
transmission that would have been missed by looking at infection prevalence results alone. In
addition by comparing areas of high seropositivity (suggesting areas of past transmission) with
areas of PCR positivity (current transmission) it is also possible to explore areas of potential
high receptivity to complement surveillance efforts and guide programmes on optimal imple-
mentation of malaria control interventions. These higher transmission areas appear to be
largely concentrated in north-west Myanmar, in the region of Sagaing, south-east in Rakhine
and in the south-western tip of Myanmar in Mon, Kayin and Thanintharyi. Interpreting these
areas as sites of high transmission requires the assumption that the infections were transmitted
in the same location as that in which the diagnosis took place, which may not always be the
case, particularly in areas with high population mobility. Although not presented here, basic
travel history information was collected as part of the MIS questionnaire and only seven indi-
viduals had travelled outside the same state/region as their household in the previous six
months. All other identified travellers had stayed away from home overnight but remained
within the same state/region. Furthermore, whilst seroprevalence in children aged less than
five years for both P. falciparum (2.33%) and P. vivax (1.41%) was low some had notable anti-
body responses, which, since young children are less likely to have travelled, indicates possible
local and recent transmission (Fig 3). Future work might include antibody responses to
recently described antigens that allow more discriminatory assessments of time since infection
and sero-incidence [37, 38].
Secondly, serology provided an increased sample size of infections with which to analyse
risk factors, improving uncertainty around OR estimates. This is useful programmatically to
guide best targeting of resources, particularly as resources become more finite following reduc-
tion in caseloads. The recent National Strategic Plan has rightly specified activities for these
risk groups such as, introducing quarterly malaria screening and additional LLINs for preg-
nant women through antenatal care services; emphasising case detection and treatment for
forest-goers and mobile groups and engaging NGO networks in distribution of ‘forest-pack-
ages’ for forest-goers; and monitoring arrival of mobile population groups into communities
by VHVs [3].
The findings offer important insights into malaria epidemiology in Myanmar, though the
survey does have certain limitations. The proportion of non-response from household mem-
bers was higher than anticipated and disproportionately consisted of males, travellers and chil-
dren aged less than five years across all domains with the exception of D4 that had a younger
population structure than the other three domains. Males and travellers were identified as risk
groups and thus overall prevalence and seroprevalence may be slightly underestimated.
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Although attempts to revisit households were made, missing a certain proportion of household
members is unavoidable and is expected to miss more mobile population groups. In contrast,
pregnant women were overrepresented since, assumedly, they are more likely to be at home
during day time. Despite not reaching the desired sample size, the loss in power to calculate
the prevalence estimates was negligible. Finally, comparison of API and prevalence data is lim-
ited because API was only available at township level and did not include infections that might
have been treated outside the formal health system. For comparison, we aggregated prevalence
to township but townships are thus only represented by one or two villages, which with high
amount of transmission heterogeneity may not be accurate. Work is ongoing in the country to
measure and report API at village level; once this is achieved better understanding of the asso-
ciation between these two measures could be elucidated.
Despite these limitations, the survey presents the first nationwide malaria prevalence base-
line findings for the Myanmar NMCP and partners as they move further toward malaria pre-
elimination and elimination goals. The utility of these findings would be maximised if future
surveys were to be regularly conducted from which to measure progress toward elimination of
malaria. Use of PCR and particularly serology would enable monitoring of changes in trans-
mission intensities to inform targeting of future interventions and ultimately certify elimina-
tion status [39]. Identified hotspots should be further investigated to determine reasons for
high prevalence and where exactly transmission is occurring, with appropriate interventions
put in place with urgency.
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